Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 3, 2013, Pages 529-533

  Zelefsky, Michael J ^a   Gomez, Daniel R ^a   Polkinghorn, William R ^a   Pei, Xin ^a   Kollmeier, Marisa ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DISEASES; PATHOLOGY; PATIENT MONITORING; PATIENT TREATMENT; RADIATION; RISK ANALYSIS; RISK ASSESSMENT; TUMORS; UROLOGY;

ANDROGEN DEPRIVATION THERAPY; CAUSE-SPECIFIC SURVIVAL; EXTERNAL BEAM RADIATION THERAPY; LOCALIZED PROSTATE CANCER; METHODS AND MATERIALS; MULTIVARIABLE ANALYSIS; PROSTATE SPECIFIC ANTIGEN; RETROSPECTIVE ANALYSIS;

RADIOTHERAPY;

BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; GONADORELIN; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; TREATMENT OUTCOME; ADJUVANT THERAPY; BLOOD; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RETROSPECTIVE STUDY;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TOSYL COMPOUNDS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880597376     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.02.004     Document Type: Article

References (13)

1. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066-1073.
2. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-1290.
3. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-2504.
4. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-1252.
5. Zelefsky MJ, Lyass O, Fuks Z, et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 1998;16:3380-3385.
6. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-881.
7. Zelefsky MJ, Pei X, Chou JF, et al. Dose escalation for prostate cancer radiotherapy: Predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011;60:1133-1139.
8. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
9. Alexander A, Crook J, Jones S, et al. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer' An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 2010;76:23-30.
10. Ludgate CM, Bishop DC, Pai H, et al. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: The importance of PSA nadir before radiation. Int J Radiat Oncol Biol Phys 2005;62:1309-1315.
11. Mitchell DM, McAleese J, Park RM, et al. Failure to achieve a PSA level
12. Sumi M, Ikeda H, Tokuuye K, et al. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma. Int J Radiat Oncol Biol Phys 2000;48:519-528
13. Malik R, Jani AB, Liauw SL. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;79:1022-1028.